These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29197465)

  • 41. Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.
    Sethi G; Sung B; Aggarwal BB
    Adv Exp Med Biol; 2009; 647():207-15. PubMed ID: 19760077
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunotherapy of autoimmune disease with anti-T cell antibodies.
    Sriram S
    Concepts Immunopathol; 1989; 7():162-72. PubMed ID: 2676177
    [No Abstract]   [Full Text] [Related]  

  • 43. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting T cell metabolism for therapy.
    O'Sullivan D; Pearce EL
    Trends Immunol; 2015 Feb; 36(2):71-80. PubMed ID: 25601541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases.
    Talotta R; Rucci F; Canti G; Scaglione F
    Immunotherapy; 2019 Feb; 11(3):241-254. PubMed ID: 30730275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of IL-17 and IL-22 in autoimmunity and cancer.
    Blake SJ; Teng MW
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():41-50. PubMed ID: 25398491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulation of autoimmune and systemic inflammatory diseases with intravenous immunoglobulin.
    Mouthon L; Piketty C; Kazatchkine MD
    Vox Sang; 1994; 67 Suppl 3():53-9. PubMed ID: 7975512
    [No Abstract]   [Full Text] [Related]  

  • 48. Proinflammatory S100 proteins in arthritis and autoimmune disease.
    Foell D; Roth J
    Arthritis Rheum; 2004 Dec; 50(12):3762-71. PubMed ID: 15593206
    [No Abstract]   [Full Text] [Related]  

  • 49. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 50. Anti-TcR antibodies in autoimmune diseases.
    Boitard C; Sempé P; Bach JF
    Immunol Ser; 1993; 59():167-73. PubMed ID: 8096399
    [No Abstract]   [Full Text] [Related]  

  • 51. 24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".
    Joalland N; Ducoin K; Cadiou G; Rabu C; Guillonneau C
    Front Immunol; 2021; 12():738312. PubMed ID: 34539674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases.
    Oflazoglu E; Grewal IS; Gerber H
    Adv Exp Med Biol; 2009; 647():174-85. PubMed ID: 19760074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoclonal antibodies.
    Diamond B; Scharff MD
    JAMA; 1982 Dec; 248(23):3165-9. PubMed ID: 7143696
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunological treatment of autoimmune diseases.
    Kalden JR; Breedveld FC; Burkhardt H; Burmester GR
    Adv Immunol; 1998; 68():333-418. PubMed ID: 9505094
    [No Abstract]   [Full Text] [Related]  

  • 55. The autoinflammatory side of systemic sclerosis.
    De Santis M; Selmi C
    Isr Med Assoc J; 2015 Jan; 17(1):47-9. PubMed ID: 25739177
    [No Abstract]   [Full Text] [Related]  

  • 56. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases.
    Kuwabara T; Ishikawa F; Kondo M; Kakiuchi T
    Mediators Inflamm; 2017; 2017():3908061. PubMed ID: 28316374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Third Interdisciplinary Symposium on the Treatment of Autoimmune Disorders, 8-10 June 2002, Leipzig, Germany.
    Amital H
    Isr Med Assoc J; 2002 Nov; 4(11 Suppl):973-6. PubMed ID: 12455196
    [No Abstract]   [Full Text] [Related]  

  • 58. Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.
    Ostrov BE
    Immunol Invest; 2015; 44(8):777-802. PubMed ID: 26575464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Skewed T-cell receptor repertoire: more than a marker of malignancy, a tool to dissect the immunopathology of inflammatory diseases.
    Pandolfi F; Cianci R; Casciano F; Pagliari D; De Pasquale T; Landolfi R; Di Sante G; Kurnick JT; Ria F
    J Biol Regul Homeost Agents; 2011; 25(2):153-61. PubMed ID: 21880203
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapeutic potential of bispecific antibodies.
    van de Winkel JG; Bast B; de Gast GC
    Immunol Today; 1997 Dec; 18(12):562-4. PubMed ID: 9425731
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.